HighTower Advisors’s Aprea Therapeutics APRE Stock Holding History

HighTower Advisors’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Hold	13,864	–	–	﹤0.01%	3784
2026 Q1	$10.6K	Hold	13,864	–	–	﹤0.01%	3784
2025 Q4	$11.8K	Hold	13,864	–	–	﹤0.01%	3632
2025 Q3	$20.4K	Hold	13,864	–	–	﹤0.01%	3672
2025 Q2	$23.4K	Hold	13,864	–	–	﹤0.01%	3606
2025 Q1	$28.3K	Hold	13,864	–	–	﹤0.01%	3496
2024 Q4	$45.6K	Hold	13,864	–	–	﹤0.01%	3466
2024 Q3	$38K	Hold	13,864	–	–	﹤0.01%	3439
2024 Q2	$56K	Hold	13,864	–	–	﹤0.01%	3291
2024 Q1	$93K	Buy	+13,864	New	+$86.2K	﹤0.01%	3164

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HighTower Advisors's APRE Position: Q2 2026 in Review

HighTower Advisors held its Aprea Therapeutics (APRE) position steady in Q2 2026 at 13,864 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3784.

HighTower Advisors first reported a position in APRE in Q1 2024 and has held it in 10 quarters since. The position peaked at $93K in Q1 2024. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

HighTower Advisors held 13,864 shares of Aprea Therapeutics worth $11.1K as of Q2 2026.
HighTower Advisors left its Aprea Therapeutics share count unchanged in Q2 2026.
Aprea Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3784 holding.
HighTower Advisors first reported a position in Aprea Therapeutics in Q1 2024 and has held it in 10 quarters since.
HighTower Advisors's Aprea Therapeutics position peaked at $93K in Q1 2024.
28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.